文献速递血栓与止血

2025年免疫性血小板减少症临床试验更新

2025 update on clinical trials in immune thrombocytopenia.
PubMed 文献 · Am J Hematol · 2024-08-06

过去二十年血小板生成素受体激动剂的发展与监管批准改变了免疫性血小板减少症(ITP)的治疗格局,但仍存在许多高度未满足的需求。目前多种在研究药物和重定位药物正在ITP中进行临床开发,与以往主要关注持续或慢性ITP无限期治疗的试验不同,正在进行的试验覆盖疾病各阶段,包括在疾病早期评估旨在改变疾病进程的新药。许多在研药物靶向当前药物未曾靶向的疾病病理生理机制,包括血小板自身抗体再循环、B细胞成熟与分化、长寿命浆细胞和补体系统等。这些药物为难治性或对现有治疗不耐受的患者提供了有前景的治疗选择。随着对ITP中多样免疫机制理解的深入,治疗武器库扩展至靶向不同病理生理机制的药物,可能在未来实现更个性化的治疗选择。本文对近期完成和正在进行的ITP临床试验进行了最新、深入的综述。

要点

  • 过去二十年TPO-RA的发展与监管批准改变了ITP治疗格局,但仍存在许多高度未满足的需求。
  • 正在进行的试验覆盖疾病各阶段,包括在疾病早期评估旨在改变疾病进程的新药。
  • 许多在研药物靶向血小板自身抗体再循环、B细胞成熟与分化、长寿命浆细胞和补体系统等新机制。

核心结论

  • 多种在研究药物和重定位药物正在ITP中进行临床开发,为难治性或对现有治疗不耐受的患者提供有前景的治疗选择。
  • 随着对ITP多样免疫机制理解的深入,靶向不同病理生理机制药物的扩展可能在未来实现更个性化的治疗选择。

研究设计与样本

  • 本文为综述,对近期完成和正在进行的ITP临床试验进行了最新、深入的概述。

主要发现

  • 过去二十年血小板生成素受体激动剂的发展与监管批准改变了ITP治疗格局,但仍存在许多高度未满足的需求。
  • 与以往主要关注持续或慢性ITP无限期治疗的试验不同,正在进行的试验覆盖疾病各阶段,并包括在疾病早期评估旨在改变疾病进程的新药。
  • 许多在研药物靶向当前药物未曾靶向的疾病病理生理机制,包括血小板自身抗体再循环、B细胞成熟与分化、长寿命浆细胞和补体系统等。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the development and regulatory approval of the thrombopoietin receptor agonists revolutionized aspects of the immune thrombocytopenia (ITP) treatment landscape over the past two decades, there remain many areas of high unmet need. Therefore, a number of investigational and repurposed agents are currently undergoing clinical development in ITP. In a departure from historical trials, which largely focused on the indefinite treatment of persistent or chronic ITP, ongoing trials run the gamut of disease phases, and include novel agents being evaluated in early phases of the disease to attempt to modify the disease course. Many agents in development target disease pathophysiologic mechanisms not previously targeted by agents in current use, including platelet autoantibody recycling, B-cell maturation and differentiation, long-lived plasma cells, and the complement system, among others. These agents represent promising treatment options for patients with otherwise refractory disease or who are intolerant of currently available therapies. Additionally, with our increasing understanding of the diverse immune mechanisms at play in ITP, the expansion of the therapeutic armamentarium to include agents targeting diverse pathophysiologic mechanisms may allow a more personalized therapeutic selection in the future. This manuscript provides an up-to-date, in-depth overview of recently completed and ongoing clinical trials in ITP.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H. 2025 update on clinical trials in immune thrombocytopenia. Am J Hematol. 2024. PMID: 39105413. doi:10.1002/ajh.27448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。